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June 20101352 Albuquerque Jr et alopen repair, with both modalities becoming safer during
the past 5 years. Treatment of AAA has become safer, with
the overall mortality (including ruptures) reduced 64%
(from 4.9% to 1.8%) during the 13-year study period.
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Dr Ross Milner (Atlanta, Ga): As demonstrated in this
manuscript and this presentation, many centers have seen a dra-
matic change in the management of aneurysms. The results of the
DREAM [Dutch Randomised Endovascular Aneurysm Manage-
ment] and the EVAR-1 [Comparison of Endovascular Aneurysm
Repair with Open Repair in Patients with Abdominal Aortic An-significant difference in the perioperative mortality rates of endo-
vascular open repair that is three times in favor of endovascular
repair. In addition, reports by Dr Schermerhorn in the New
England Journal of Medicine have shown this perioperative mor-
tality rate difference to be true especially in older patients. The
initial mortality rate difference seems to go away a little bit over
time with both the DREAM and EVAR-1 trials, but this does not
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still remains a strong enthusiasm for endovascular repair.
Your paper is a very nice review of 13 years’ worth of experi-
ence of open and endovascular repair at a single institution, and the
main goal, as you said, was to demonstrate the rate of adoption.
And I know you highlighted some of the limitations and those are
some of the questions I am going to bring up.
The authors show a bimodal distribution of adoption with
an over 80% rate of AAAs [abdominal aortic aneurysms] being
treated in an endovascular fashion. You have shown that initially
there was some decrease in enthusiasm after the initial device
showed some concern for problems, and as the second-genera-
tion of devices have been introduced, a greater adoption of
endovascular repair. In your center, as you said, the majority
have been Zenith. I think around the country there is a different
distribution of devices depending on the center, but similar
widespread adoption of endovascular repair.
You show both a low mortality rate with both open and
endovascular repair. Your open mortality rate obviously was
higher, as would be expected, but included aneurysms that re-
quired both suprarenal and supraceliac clamping as well as renal
artery revascularizations. You show an improvement in outcomes in
all patients in your later period, and I think in addition you should be
congratulated for an overall low mortality rate with ruptures.
Major limitations of this work are that the authors do not include
any of the standard anatomic variables that we usually use to assess
candidacy for endovascular therapy as well as report on any endoleak
analysis that occurred perioperatively or long term.
So first of all, how many of your patients treated by EVAR had
adjuncts, such as placement of a Palmaz stent, performed during initial
device placement? Just to give us a better idea to understand how many
patients were appropriate candidates based on appropriate IFU [instruc-
tions for use] or how many people were using challenging anatomy that
you are trying to expand your indications for endograft therapy.
As mentioned above, and as you said in your presentation, there
is no endoleak data currently in this manuscript. I think it is very
important to document the endoleaks, especially with potentially type
I from neck issues considering your very widespread adoption of
endovascular therapy, because if there are long-term consequences of
rupture or aneurysm expansion, you may rethink the overall high rate
of use. So therefore, what is your endoleak rate in your series, your rate
of secondary interventions, and as a follow-up, are there any conver-
sions to open repair in your over 400 endografts that you placed?
One other concern is the use of endografts in younger pa-
tients. Have you looked at how you treat patients younger than 65
years old? Specifically, of patients younger than 65, how many were
treated by endografts, how many had open repair, and what is your
mortality rate in this selected group of patients?
And finally, I, as well as you, have a particular interest in the
complexity of open AAA repairs performed in tertiary medical
care centers with the widespread use of EVAR. The majority of
these open repairs, as you mentioned, require complex manage-
ment of the visceral segment of the aorta. You clearly described
three categories: The first is just an infrarenal clamp; the second
requires a suprarenal or supraceliac clamp; and the third one is
the same higher level of clamping but with renal artery revascu-
larizations. Have you looked at the different mortality rates in
these three groups, especially when you compare the difference
between the suprarenal or supraceliac clamping and renal artery
revascularizations, and is the mortality rate of an infrarenal
clamp alone equivalent to an endovascular repair?
Dr Francisco Albuquerque: In regards to the adjunctive
treatment, we don’t have the data specifically in this paper. We had
performed endovascular repair in complex anatomy outside IFU,
and we have some preliminary data on our research on secondary
intervention that we intend to publish later. Our service published
a paper in the Journal of Vascular Surgery, I think in May 2008,
about technical notes in Palmaz stent placement, where they had
20 Palmaz stents placed. On our preliminary data from the second-
ary procedure research, I found that at least 15 were done in the2003 to 2008 period for the initial procedure. The other five could
have been done in the first period or later during follow-up.
For the secondary procedures and endoleak rates, we will show the
dataonthesecondaryprocedurepaper. Itwasnot the intentonthiswork.
We also had a paper published in 2002 about secondary procedure, and
the incidence was around 20%. I have preliminary data that show a
probable significant decrease in secondary intervention in the second
periodand ithasbeenaround10%.ThePalmazstentplacementprobably
reflects the type I endoleak at the initial procedure that we dealt with.
In terms of conversion, looking again at the data for secondary
procedure, I found about 14 conversions, 7 at the initial procedure,
and 7 later. But all the 14 conversions were done in the subgroup of
patients that had the endograft placed in the first period. We actually
had one conversion recently, about 3 months ago, that would not be
on that study because it was not done in the study period.
We do not have the data on utilization of endografts in younger
patients. In our institution, we usually offer and perform EVAR if the
patient has a very good anatomy, even in the younger patients. If there is
a questionable good anatomy for EVAR and there is no doubt that the
patient is a good surgical risk, we usually perform an open repair.
Regarding the complexity of open AAA repairs, we did not
look at the different mortality rates for the different levels of aortic
clamping for open repair. We have a very small sample size for
those, and the mortality difference probably would not be statisti-
cally significant. We excluded the patients that required renal artery
reimplantation. I agree that in order to have a “fair” comparison,
we should be comparing the EVAR mortality with the mortality of
the open AAA repair that required infrarenal clamp. I don’t think
that it would be possible to have a randomized trial to compare
EVAR vs open AAA repair in patients with difficult anatomy such
as a very short and/or angulated neck. We may have an answer if
you look at a large registry, like the EUROSTAR [European Col-
laborators on Stent-Graft Techniques for Aortic Aneurysm Repair],
that probably has more than 8,000 to 10,000 patients. I guess that
there are some groups that are performing EVAR with difficult
anatomy outside IFU after they have gone with the pivotal trials.
Dr William Jordan Jr (Birmingham, Ala): First, while I see
your comment here on your last slide about you think some grafts
are better, do you have that much confidence that this is really
related to the better Zenith graft? I know we don’t want to be too
commercial here, but that is one question.
The other question is, consider the training paradigm that you
are in now, I’d like to know how you feel about doing open repair
now when you’re seeing 70%, 80%, and even 90% of your aneu-
rysms done with endo as opposed to open? Do you feel good about
having that open experience?
Dr Albuquerque: I don’t think it is related basically just to
the Zenith device but to the newer endografts with active fixation
and better engineering. The devices with suprarenal fixation may
play a role, but we may have some bias on that. We sometimes treat
type I endoleak with a Palmaz stent that works also with the
principal of suprarenal fixation. It looks intuitive, and it does not
cause a problem with renal perfusion.
I also showed that there was an increase in the utilization of
the Excluder device that does not have suprarenal fixation but it is
part of the newer generation endografts. It has a lower profile and
may be better for certain anatomic configuration such as female
with small iliac arteries.
What was the last question?
Dr Jordan: Your open experience.
Dr Albuquerque: People would say that you should see one,
help one, and do the third one. Maybe the saying is “see one, do one,
and teach one.” I am more conservative. I don’t think it would be
much different if you are doing this, as long as you can still have some
good training on doing more complex AAA repair. It would depend
on the number of those complex cases. I think that you still could have
a good open experience without doing a huge number of open cases.
We also have the aortoiliac occlusive disease where you will be doing
work on the aorta that will help us with the open repair experience.
